Work Here?
Industries
Biotechnology
Healthcare
Company Size
10,001+
Company Stage
IPO
Headquarters
Madison, Wisconsin
Founded
1967
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$750M
Above
Industry Average
Funded Over
1 Rounds
In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer’s disease pathology with greater than 90% sensitivity and specificity SECAUCUS, N.J., April 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI) or dementia. The laboratory-developed test, named AD-Detect™ Abeta 42/40 and p-tau217 Evaluation, combines results of blood levels of amyloid beta (AB) 42/40 determined by the company’s proprietary tandem mass spectrometry techniques with blood levels of p-tau217 determined by an in vitro immunoassay test. The test results are then used to produce the AD-Detect Likelihood Score™, a composite interpretation created through a proprietary algorithm validated utilizing a well-characterized cohort from the 1Florida Alzheimer’s Disease Research Center (ADRC). The new Quest test panel builds on prior AD-Detect tests that individually assess AB 42/40 and p-tau217, as well as p-tau181 and the ApoE isoform, a genetic risk marker. Those tests help providers assess risk of AD rather than confirm likelihood of amyloid brain pathology due to AD. “Quest’s AD-Detect suite of advanced diagnostics has grown to include a range of validated blood-based biomarkers, giving providers options for personalizing testing for the individual patient,” said Kathleen Valentine, Vice President and General Manager, Neurology, Quest Diagnostics
Quest Diagnostics today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or dementia.
Quest Diagnostics introduces HPV specimen self-collection for cervical cancer screening.
Quest Diagnostics, a leading provider of diagnostic information services, has announced a strategic collaboration with Google Cloud to enhance data management, streamline operations, and personalize experiences for patients, healthcare providers, and other customers using generative AI (gen AI) technologies.Under the partnership, Quest, located in Secaucus, will deploy Google Cloud’s AI-powered solutions, including Google Agentspace, an enterprise platform that uses gen AI to integrate company-wide knowledge and automate complex tasks through intelligent agents. This initiative represents one of the first large-scale applications of gen AI by a national laboratory provider, optimizing functions across research & development (R&D), customer engagement, and operations—while maintaining strict data privacy and security measures.“We are excited about the potential to innovate and personalize the services we bring to our patients, clients, and employees,” said Murali Balakumar, senior vice president and chief information and digital officer, Quest Diagnostics. “Google Cloud provides a best-in-class platform for securely integrating data to generate insights and improve productivity. By leveraging generative AI, we can remove barriers to care, enhance provider-patient interactions, and improve access to quality health care services.”Quest will utilize Google Cloud’s advanced AI to enhance data integration, security, and analytics, while also exploring AI-driven solutions in key areas such as:Patient Engagement: Using gen AI to help patients access and interpret their lab data, providing more personalized health insights.Physician Support: Empowering providers with real-time lab insights and clinical data to aid in individualized patient care.Operational Efficiency: Automating administrative and workflow processes to improve service delivery and productivity.“Working with Google Cloud will allow us to create new capabilities for serving patients, health care providers, and other customers,” said Mark S. Clare, vice president and chief data officer, Quest Diagnostics. “Data management is evolving rapidly with AI, and this collaboration will ensure Quest remains at the forefront of responsible, secure, and innovative data use in healthcare.”The collaboration strengthens Quest’s hybrid cloud strategy, expanding its AI capabilities to improve scalability and efficiency
Generative AI in Diagnostics: Quest Partners with Google Cloud for Enhanced Data Insights. by Fred Pennic 03/18/2025 Leave a Comment. What You Should Know: – Quest Diagnostics, a provider of diagnostic information services announced a strategic collaboration with Google Cloud to enhance its data management, improve data analytics, and personalize customer experiences. – The partnership will leverage Google Cloud’s advanced data analytics and generative AI (gen AI) technologies to transform various aspects of Quest’s operations.Google Agentspace IntegrationA key component of this collaboration is the integration of Google Agentspace, a platform that utilizes gen AI to connect employees and customers with enterprise-wide knowledge. This will automate complex tasks through intelligent, customizable agents, marking one of the first implementations of these technologies by a national laboratory provider across RD, customer experience, and operations, all while maintaining stringent data privacy and security.Enhanced Data Analytics – Utilizing Google Cloud’s data analytics tools will enable Quest to gain deeper insights from its vast data sets. Gen AI will be explored to provide patients and consumers with personalized health insights derived from their laboratory data. Physicians will gain access to enhanced laboratory insights and other data, facilitating improved patient care
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
10,001+
Company Stage
IPO
Headquarters
Madison, Wisconsin
Founded
1967
Find jobs on Simplify and start your career today